Do we need a Wider Therapeutic Paradigm for Heart Failure with Comorbidities? - A Remote Australian PerspectiveIyngkaran P1,2,3,5*, Thomas M2, Sanders P4, Hare DL6, Majoni W1, Brady S7, Nadarajan K1,3, Ilton M1,3 and Brown A8
- Corresponding Author:
- Pupalan Iyngkaran
Cardiologist Royal Darwin Hospital
Senior Lecturer Flinders University
Research Fellow Baker IDI/FHBHRU Darwin Private Hospital
Rocklands Drive, Tiwi, NT 0811, Australia
E-mail: [email protected]
Received date: August 24, 2013; Accepted date: October 18, 2013; Published date: October 20, 2013
Citation: Iyngkaran P, Thomas M, Sanders P, Hare DL, Majoni W, et al. (2013) Do we need a Wider Therapeutic Paradigm for Heart Failure with Comorbidities? - A Remote Australian Perspective. Health Care Current Reviews 1:106. doi:10.4172/hccr.1000106
Copyright: © 2013 Iyngkaran P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract Congestive Heart Failure a leading cause of morbidity and mortality is often associated with comorbidities and with it polypharmacy. Improved pathophysiological understanding, the available therapeutics, clinical guidelines and structured programs for comprehensive care have not benefited all clients in the Northern Territory of Australia. The Northern Territory has both a unique geography and demography including a sizeable Indigenous population. Additional factors that can affect heart failure management are prevalent in remote areas and are not well addressed within randomized controlled trials. This review is focused on building a case for widening the therapeutic paradigm for heart failure with comorbidities. We focus on a brief overview of heart failure and its associated comorbidities, the common overlapping physiological processes, the interpretation of the external validity of trial evidence, and finally exploring the available evidence for the important therapies within the guidelines. A need to consider a wider therapeutic paradigm may also have relevance for clients in other health systems.